Publicité
Publicité
XLO
Xilio Therapeutics, Inc. Common Stock
0.70
USDSponsorisé
-0.03
-3.66%
09 janv., 12:54 UTC -5
Ouvert
XLO Rapports sur les bénéfices
Ratio de surprise positive
XLO a dépassé 10 des 17 dernières estimations.
59%
Prochain rapport
Date du prochain rapport
09 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.04M
/-$0.12
Variation implicite de Q3 25 (Revenue/ EPS)
-57.83%
/--
Variation implicite de Q4 24 (Revenue/ EPS)
+366.33%
/-40.00%
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On 13 nov. 2025, XLO reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.03 USD, resulting in a 80.20% surprise. Revenue reached 19.07 million, compared to an expected 18.82 million, with a 1.30% difference. The market reacted with a -9.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 analystes forecast an EPS of -0.12 USD, with revenue projected to reach 8.04 million USD, implying an -- of --% EPS, and baisse of -57.83% in Revenue from the last quarter.
FAQ
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Xilio Therapeutics, Inc. Common Stock reported EPS of $0.00, beating estimates by 80.2%, and revenue of $19.07M, 1.3% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -9.28%, changed from $0.77 before the earnings release to $0.70 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 09 mars 2026.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on 2
analystes, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $8.04M for Q4 2025.
Which companies are reporting earnings today?
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité